Get started
Author

Eve Fishinevich

ORCID: 0000-0002-1808-9213
Observed ORCID: 0000-0002-1808-9213
OpenAlex ID: A5079744252
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
2022 · Amish J. Patel, Sarah Warda, et al. · Cancer Discovery · 34
PDF
MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al. · Clinical Cancer Research · 12
Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy
2023 · Fabio Vanoli, Laurie Herviou, et al. · Oncogenesis · 8
PDF
Modeling Extraordinary Response Through Targeting Secondary Alterations in Fusion-Associated Sarcoma
2024 · Fabio Vanoli, Evan Song, et al. · JCO Precision Oncology · 3
PDF
Data from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al. · 1
PRC2 Restricts Malignant Peripheral Nerve Sheath Tumorigenesis in a Genetically Engineered Mouse Model of MPNST
2025 · Woo Hyun Cho, Amish J. Patel, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Supplementary Table S2 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Figure S1 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Figure S4 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Figure S6 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Figure S3 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
PDF
Supplementary Figure S5 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Table S4 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Figure S7 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Figure S2 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Table S3 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Table S5 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Supplementary Table S1 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
2024 · Miguel A. Miranda-Román, Cindy J. Lee, et al.
Data from PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
2023 · Amish J. Patel, Sarah Warda, et al.
Data from PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
2023 · Amish J. Patel, Sarah Warda, et al.
Supplementary Data from PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
2023 · Amish J. Patel, Sarah Warda, et al.
Supplementary Data from PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
2023 · Amish J. Patel, Sarah Warda, et al.
Supplementary Data from PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
2023 · Amish J. Patel, Sarah Warda, et al.
Supplementary Data from PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
2023 · Amish J. Patel, Sarah Warda, et al.
PDF
Abstract PR005: PRC2 inactivating mutations amplify cell death in response to DNMT1-targeted therapy through enhanced viral mimicry in malignant peripheral nerve sheath tumor
2022 · Ping Chi, Amish J. Patel, et al. · Clinical Cancer Research
Works count: 26
Citation count: 58
H-index: 3
I10-index: 2
Year
Topic
Type